Skip to main content
. 2018 Oct 19;19:268. doi: 10.1186/s12882-018-1068-1

Table 5.

Comparison of survival on CRRT by principal diagnosis, weight, CRRT indication, and immune status between study eras and shown over the 10 year study period

2004–2008 2009–2013 2004–2013
Survivor
n (%)
Survivor
n (%)
Survivor
n (%)
Principal Diagnosis Category
 Cardiac 7 (54%) 3 (27%) 10 (42%)
 Renal 4 (44%) 14 (74%) 18 (64%)
 Liver 6 (32%) 17 (46%) 23 (41%)
 Hematology/Oncology a 10 (56%) 3 (18%) 13 (37%)
 Bone marrow transplant 3 (17%) 5 (33%) 8 (24%)
 Pulmonary 4 (36%) 2 (50%) 6 (40%)
 Inborn error of metabolism 5 (100%) 7 (70%) 12 (80%)
 Sepsis 3 (30%) 2 (40%) 5 (33%)
 Neonates 8 (80%) 8 (62%) 16 (70%)
 Other b 10 (63%) 10 (77%) 20 (69%)
Weight
 0-10 kg 9 (35%) 19 (50%) 28 (44%)
 10-25 kg 13 (45%) 22 (56%) 35 (51%)
 25-50 kg 17 (49%) 13 (39%) 30 (44%)
 > 50 kg 21 (54%) 17 (50%) 38 (52%)
Indications for CRRT
 Fluid overload 31 (42%) 35 (49%) 66 (46%)
 Fluid overload & electrolyte management 12 (43%) 17 (41%) 29 (41%)
 Prevent fluid overload/provide nutrition 3 (50%) 2 (67%) 5 (56%)
 Electrolyte management 4 (57%) 4 (44%) 8 (50%)
 Other c 10 (71%) 13 (68%) 23 (70%)
Days on CRRT
 1 day 8 (47%) 5 (55%) 12 (50%)
 2–7 days 24 (42%) 34 (45%) 58 (44%)
 8–14 days 18 (50%) 12 (36%) 30 (43%)
 15–21 days 10 (53%) 11 (48%) 21 (50%)
 22–28 days 1 (17%) 7 (50%) 8 (40%)
 > 28 days 3 (25%) 7 (50%) 10 (38%)
Immune Status
 Solid organ transplant 11 (44%) 17 (52%) 28 (48%)
 Bone marrow transplant 5 (29%) 5 (36%) 10 (32%)
 Other immunocompromised 12 (48%) 11 (42%) 23 (45%)
 Not immunocompromised 32 (52%) 38 (54%) 70 (53%)

ap < 0.05 comparing 2004–2008 survivors with 2009–2013 survivors

bIncludes rheumatologic, gastroenterologic, multiple organ, neurologic, ingestions, hemorrhage, rhabdomyolysis, and non-accidental trauma

cIncludes hemodynamic instability, hyperammonemia, ingestion, and end-stage renal disease